Table 6. . Scenario analyses.

Scenario	ICER (Cost/QALY) for Pegcetacoplan vs
	Eculizumab	Ravulizumab
Mean weight (63.72 kg)	Dominant	$94,568
Incremental number of transfusions per cycle equal to 0	Dominant	Dominant
Time horizon
5 years	Dominant	Dominant
10 years	Dominant	Dominant
25 years	Dominant	Dominant
End point definition
Hemoglobin normalization – proportion estimated with Weibull distribution	Dominant	Dominant

ICER: Incremental cost–effectiveness ratio, QALY: Quality-adjusted life year.